For 25 formula targets sharing with the targets of 30 FDA proved RA drugs (Fig. 3a), six of them cover the targets of four current prevalent drugs (LEF, Temsirolimus, Etoricoxib and Infliximab), e.g. TNF, DHODH (dihydroorotate dehydrogenase [quinone]), MTOR (mechanistic target of rapamycin [serine/threonine kinase]), PTGS2 (Prostaglandin G/H synthase 2), AHR (aryl hydrocarbon receptor), PTK2B (protein-tyrosine kinase 2-beta). Here, PTK2B is linked to rheumatoid arthritis.